Sionna Therapeutics announced that its Phase 2a trial for SION-719 in cystic fibrosis (CF) did not meet its key endpoint, leading the company to discontinue the program as an add-on to standard of care. The company is now preserving capital while it evaluates the next steps for its related SION-451 dual combination program.
Key Details
- Trial Results: The Phase 2a PreciSION CF trial for SION-719 failed to meet its key activity endpoint, showing a non-significant mean placebo-adjusted sweat chloride change of -1.0 mmol/L (p=0.7).
- Program Status: The company will not advance SION-719 as an add-on therapy. It is currently evaluating the future of its SION-451 dual combination program, despite its Phase 1 trial meeting safety and PK objectives.
- Financial Position: Sionna ended Q2 with approximately $268.3 million in cash and intends to take actions to preserve capital following the clinical trial results.